Calendario›INO›INO-3401 + EP
INO-3401 + EP
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
Ensayo de INOVIO PHARMACEUTICALS, INC. en Voluntarios sanos.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 22
- Centros
- 2
- Fin del objetivo primario
- ago 2012
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en may 2011.
Qué mide
Safety (del registro, en inglés) (del dia 0 al mes 9)
Cómo lo describe el promotor
En el documentoEn inglés, del registroDNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans. The investigators have developed a DNA vaccine, INO-3401, which includes plasmids targeting the proteins of the H5N1 avian influenza virus. The vaccine will be delivered via electroporation (EP) which uses the CELLECTRA constant current device to deliver a small electric charge following injection, since animal studies have shown that this delivery method increases the immune response to vaccine. The vaccine will be given to up 30 healthy adult subjects who have participated in study FLU-001. It is hypothesized that a booster dose with INO-3401 + EP will be well tolerated and immunogenic.
Más ensayos de INO
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| INO-5401 | Fase 1/2 | En marcha, sin reclutar | dic 2026 (prevista) |
| INO-5401 | Fase 1/2 | Completado | may 2025 (real) |
| INO-4800 | Fase 1 | Retirado antes de empezar | mar 2024 (prevista, ya pasada: sin actualizar en el registro) |
| INO-4700 | Fase 2 | Completado | ene 2023 (real) |
| INO-3107 | Fase 1/2 | Completado | dic 2022 (real) |
| INO-4500 | Fase 1 | Completado | oct 2022 (real) |
Todos los de INO, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT01403155), actualizada en sep 2017.